Journal
MOLECULAR BIOTECHNOLOGY
Volume 64, Issue 4, Pages 355-372Publisher
SPRINGERNATURE
DOI: 10.1007/s12033-021-00422-8
Keywords
CRISPR; CRISPR-associated proteins; Nucleic acids; Non-homologous end joining; Homology-directed repair; Therapeutic applications
Ask authors/readers for more resources
The CRISPR-Cas genome editing system, part of a bacteria-based immune system, has opened up new possibilities in gene editing with the discovery of Cas proteins like Cas9, Cas12a, and Cas13. Ongoing research aims to explore the efficacy and safety of CRISPR for various applications, including therapeutic uses.
The CRISPR-Cas genome editing system is an intrinsic property of a bacteria-based immune system. This employs a guide RNA to detect and cleave the PAM-associated target DNA or RNA in subsequent infections, by the invasion of a similar bacteriophage. The discovery of Cas systems has paved the way to overcome the limitations of existing genome editing tools. In this review, we focus on Cas proteins that are available for gene modifications among which Cas9, Cas12a, and Cas13 have been widely used in the areas of medicine, research, and diagnostics. Since CRISPR has been already proven for its potential research applications, the next milestone for CRISPR will be proving its efficacy and safety. In this connection, we systematically review recent advances in exploring multiple variants of Cas proteins and their modifications for therapeutic applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available